In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Abstract Background Dendritic cells (DCs) are central for the initiation and regulation of
innate and adaptive immunity in the tumor microenvironment. As such, many kinds of DC …

The innate immune pathway is receiving increasing attention in cancer therapy. This
pathway is ubiquitous across various cell types, not only in innate immune cells but also in …

Despite its remarkable clinical breakthroughs, immune checkpoint blockade (ICB) therapy
remains limited by the insufficient immune response in the “cold” tumor. Nanozyme‐based …

Myeloid cells are the most abundant immune components of the tumour microenvironment,
where they have a variety of functions, ranging from immunosuppressive to …

The advent of immunotherapy has revolutionized the treating modalities of cancer. Cancer
vaccine, aiming to harness the host immune system to induce a tumor‐specific killing effect …

Effective cancer immunotherapy is usually blocked by immunosuppressive factors in the
tumour microenvironment, resulting in tumour promotion, metastasis and recurrence. Here …

The reversible oxidation-reduction homeostasis mechanism functions as a specific signal
transduction system, eliciting related physiological responses. Disruptions to redox …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …